Close Menu

Sema4

BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.

The firm said the New York State approval for the two tests comes soon after it launched Sema4 Signal, a family of precision oncology products and services.

Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.

Researchers will use the VCurePrecision EMR platform to improve understanding of cancer, and doctors can use it make care decisions for patients.

The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing. 

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.